• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
JIA Kang,SHEN Qianhui,ZHANG Zhixian,LIU Yuan,PI Rongbiao,ZHOU Sigui.Masitinib attenuates neuropathological changes in acrolein-induced sAD model mice[J].Journal Of Pharmaceutical Research,2025,44(6):528-535[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1998times   Download 784次 QR Code for this article
Scan with your phone!
马赛替尼减轻丙烯醛诱导的sAD模型小鼠神经病理学改变的作用研究
贾康1,沈千惠1,张志先2,刘源2,皮荣标2,周四桂1
Font:Larger+|Default|Smaller-
(1.广东药科大学药学院,广东 广州 510006;2.中山大学药学院,广东 深圳 518107)
摘要:
目的 探究马赛替尼对丙烯醛诱导的散发性阿尔茨海默病(sporadic Alzheimer's disease,sAD)小鼠模型的治疗作用及其潜在机制。方法 雄性C57BL/6小鼠灌胃丙烯醛[3 mg·(kg·d)-1]持续10周,从第5周开始同时给予马赛替尼[60 mg·(kg·d)-1]干预6周。第9周进行行为学测试,包括埋藏食物小球实验、Morris水迷宫实验、Y迷宫实验、旷场实验和高架十字迷宫实验。随后取皮层和海马组织,通过蛋白免疫印迹、免疫荧光染色和高尔基-考克斯染色进行病理检测。结果 马赛替尼显著改善丙烯醛诱导的嗅觉缺陷、认知功能障碍和焦虑样行为。此外,马赛替尼不仅能够下调p-Tau水平、增加突触蛋白PSD95表达、恢复树突棘密度,还可以通过抑制NF-κB/NLRP3/caspase-1信号通路及小胶质细胞活化发挥抗神经炎症作用。结论 首次阐明马赛替尼通过协同调控认知功能和神经保护双重机制减缓sAD病理进程,为其临床转化应用提供了重要的实验依据。
关键词:  马赛替尼  散发性阿尔茨海默病  丙烯醛  认知功能障碍  神经炎症
DOI:10.13506/j.cnki.jpr.2025.06.002
基金项目:国家自然科学基金项目(No.81671264);深圳市港澳科技计划A类项目(No.202111233000079)广州市科技计划项目(No.SL2023B03J00817)
Publication Date:June 25, 2025
Masitinib attenuates neuropathological changes in acrolein-induced sAD model mice
JIA Kang1,SHEN Qianhui1,ZHANG Zhixian2,LIU Yuan2,PI Rongbiao2,ZHOU Sigui1
(1.School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China; 2. School of Medicine, Sun Yat-sen University, Shenzhen 518107, China)
Abstract:
Objective To explore the therapeutic effects of masitinib in acrolein-induced sporadic Alzheimer's disease (sAD) model mice and explore its underlying mechanisms.Methods Male C57BL/6 mice were administered acrolein [3 mg·(kg·d)-1] by gavage for 10 weeks, with masitinib [60 mg·(kg·d)-1] co-administered from the 5th week for 6 weeks. Behavioral tests, including the buried food pellet test, Morris water maze, Y-maze, open field test, and elevated plus maze, were conducted at the 9th week. Cortical and hippocampal tissues were then collected for pathological assessments using Western blot, immunofluorescence staining, and Golgi-Cox staining.Results Masitinib significantly ameliorated acrolein-induced olfactory deficits, cognitive dysfunction, and anxiety-like behaviors. Furthermore, masitinib not only reduced phosphorylated Tau (p-Tau) levels, increased postsynaptic density protein 95 (PSD95) expression, and restored dendritic spine density but also exerted anti-neuroinflammatory effects by suppressing the NF-κB/NLRP3/caspase-1 signaling pathway and microglial activation.Conclusion This study is the first to demonstrate that masitinib mitigates sAD progression through dual mechanisms involving cognitive improvement and neuroprotection, providing crucial experimental evidence for its clinical translation.
Key words:  Masitinib  Sporadic Alzheimer's disease  Acrolein  Cognitive dysfunction  Neuroinflammation
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.